Sihuan Pharmaceutical Holdings
Sihuan Pharmaceutical Holdings Group Ltd, commonly referred to as Sihuan Pharmaceutical, is a prominent player in the pharmaceutical industry, headquartered in Beijing, China. Founded in 2001, the company has established itself as a leader in the development, manufacturing, and marketing of innovative pharmaceutical products, particularly in the fields of cardiovascular and central nervous system therapies. With a strong operational presence across major regions in China, Sihuan Pharmaceutical is renowned for its unique portfolio of prescription drugs and over-the-counter products. The company has achieved significant milestones, including the successful launch of several key medications that address critical health needs. Sihuan Pharmaceutical's commitment to research and development, coupled with its strategic market positioning, has garnered recognition within the industry, solidifying its reputation as a trusted provider of high-quality healthcare solutions.
DitchCarbon Score
How does Sihuan Pharmaceutical Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sihuan Pharmaceutical Holdings's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sihuan Pharmaceutical Holdings's reported carbon emissions
In 2022, Sihuan Pharmaceutical Holdings reported total carbon emissions of approximately 123,292,250 kg CO2e, comprising about 52,191,660 kg CO2e from Scope 1 and about 71,100,590 kg CO2e from Scope 2 emissions. The company has not disclosed emissions data for 2023, nor does it provide information on Scope 3 emissions. Sihuan Pharmaceutical has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company’s emissions intensity, measured in kg of CO2e per unit of revenue, was reported at approximately 0.00006 in 2022. The lack of significant climate commitments or reduction initiatives suggests that Sihuan Pharmaceutical Holdings is currently not aligned with industry-leading practices in carbon management. As the company continues to operate within the pharmaceutical sector in China, it may face increasing pressure to enhance its climate strategies and transparency regarding emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 47,203,480 | 00,000,000 | 00,000,000 |
| Scope 2 | 69,040,560 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sihuan Pharmaceutical Holdings is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
